In: BMC Cancer, 18 (2018), Nr. 135. pp. 1-10. ISSN 1471-2407
Preview |
PDF, English
Download (875kB) | Lizenz: Creative Commons Attribution 4.0 |
Abstract
Background: We evaluated treatment decisions and outcomes in a cohort of predominately Caucasian patients with EGFR mutation-positive (EGFR Mut+) non-small-cell lung cancer (NSCLC).
Methods: REASON (NCT00997230) was a non-interventional study in German patients with stage IIIB/IV NSCLC. Secondary endpoints for EGFR Mut + NSCLC included progression-free survival (PFS), overall survival (OS), adverse event (AE) management, and pharmacoeconomic outcomes.
Results: Among 334 patients with EGFR Mut + NSCLC, tyrosine kinase inhibitors (TKIs) were the most common first-line therapy (56.6%, 53.0% gefitinib). Among patients who received TKIs/gefitinib before first disease progression, PFS was longer compared with those who did not receive a TKI (median 10.1/10.0 vs. 7.0 months; HR 0.67/0.69; log-rank p = 0.012/p = 0.022). OS was longer for those patients who ever received a TKI/gefitinib during their complete therapy course compared with those who never received a TKI (median 18.4/18.1 vs. 13.6 months; HR 0.53/0.55; p = 0.003/p = 0.005). Total mean first-line treatment healthcare costs per person were higher for those receiving TKIs (€46,443) compared with those who received chemotherapy (€27,182). Mean outpatient and inpatient costs were highest with chemotherapy. Rash, diarrhea, and dry skin were the most commonly reported AEs for patients receiving gefitinib.
Conclusions: In REASON, TKI therapy was the most common first- and second-line treatment for EGFR Mut + NSCLC, associated with increased drug costs compared with chemotherapy. Patients who received gefitinib or a TKI ever during their complete therapy course had prolonged PFS and OS compared with patients who did not receive a TKI.
Trial registration: The trial was registered on October, 2009 with ClinicalTrials.gov : https://clinicaltrials.gov/ct2/show/NCT00997230?term=NCT00997230&rank=1
Document type: | Article |
---|---|
Journal or Publication Title: | BMC Cancer |
Volume: | 18 |
Number: | 135 |
Publisher: | BioMed Central ; Springer |
Place of Publication: | London ; Berlin ; Heidelberg |
Date Deposited: | 24 Apr 2018 07:51 |
Date: | 2018 |
ISSN: | 1471-2407 |
Page Range: | pp. 1-10 |
Faculties / Institutes: | Medizinische Fakultät Heidelberg > Pathologisches Institut Medizinische Fakultät Heidelberg > Thoraxklinik Heidelberg gGmbH |
DDC-classification: | 610 Medical sciences Medicine |